Access to pharmaceuticals

the EU picture

Research output: Contribution to conferenceOther

4 Downloads (Pure)

Abstract

There are growing concerns among European payers about the rising costs of new medicines especially for cancer and those for orphan diseases, exacerbated by the emotive nature of these disease areas –balanced against continued unmet need▪This is despite the limited health gain of most new medicines coupled with the low cost of goods of most including biological medicines. Alongside this, CEE countries are struggling to fund biological medicines for immunological diseases at Euro 1000 –1500/ patient/ month –although easier with biosimilars ▪This is leading to developments including new models for new medicines incorporating new pricing approaches for orphan diseases, calls for greater transparency in price negotiations with concerns with MEAs, development of European collaborations and position statements (EURODIS), and greater use of low cost generics and biosimilars
Original languageEnglish
Number of pages26
Publication statusPublished - 4 Dec 2019
EventAIM event in the European Parliament: Fair Prices for Pharmaceuticals - Why and How? - European Parliament, Brussels, Belgium
Duration: 4 Dec 20194 Dec 2019

Other

OtherAIM event in the European Parliament
CountryBelgium
CityBrussels
Period4/12/194/12/19

Fingerprint

Biosimilar Pharmaceuticals
Costs and Cost Analysis
Rare Diseases
Pharmaceutical Preparations
Immune System Diseases
Negotiating
Financial Management
Health
Neoplasms

Keywords

  • pharmaceutical pricing
  • pharmacoeconomics
  • health costs

Cite this

Godman, B. (2019). Access to pharmaceuticals: the EU picture. AIM event in the European Parliament, Brussels, Belgium.
Godman, Brian. / Access to pharmaceuticals : the EU picture. AIM event in the European Parliament, Brussels, Belgium.26 p.
@conference{6728c65edc6f493cbeee8410f36ff2e2,
title = "Access to pharmaceuticals: the EU picture",
abstract = "There are growing concerns among European payers about the rising costs of new medicines especially for cancer and those for orphan diseases, exacerbated by the emotive nature of these disease areas –balanced against continued unmet need▪This is despite the limited health gain of most new medicines coupled with the low cost of goods of most including biological medicines. Alongside this, CEE countries are struggling to fund biological medicines for immunological diseases at Euro 1000 –1500/ patient/ month –although easier with biosimilars ▪This is leading to developments including new models for new medicines incorporating new pricing approaches for orphan diseases, calls for greater transparency in price negotiations with concerns with MEAs, development of European collaborations and position statements (EURODIS), and greater use of low cost generics and biosimilars",
keywords = "pharmaceutical pricing, pharmacoeconomics, health costs",
author = "Brian Godman",
year = "2019",
month = "12",
day = "4",
language = "English",
note = "AIM event in the European Parliament : Fair Prices for Pharmaceuticals - Why and How? ; Conference date: 04-12-2019 Through 04-12-2019",

}

Godman, B 2019, 'Access to pharmaceuticals: the EU picture' AIM event in the European Parliament, Brussels, Belgium, 4/12/19 - 4/12/19, .

Access to pharmaceuticals : the EU picture. / Godman, Brian.

2019. AIM event in the European Parliament, Brussels, Belgium.

Research output: Contribution to conferenceOther

TY - CONF

T1 - Access to pharmaceuticals

T2 - the EU picture

AU - Godman, Brian

PY - 2019/12/4

Y1 - 2019/12/4

N2 - There are growing concerns among European payers about the rising costs of new medicines especially for cancer and those for orphan diseases, exacerbated by the emotive nature of these disease areas –balanced against continued unmet need▪This is despite the limited health gain of most new medicines coupled with the low cost of goods of most including biological medicines. Alongside this, CEE countries are struggling to fund biological medicines for immunological diseases at Euro 1000 –1500/ patient/ month –although easier with biosimilars ▪This is leading to developments including new models for new medicines incorporating new pricing approaches for orphan diseases, calls for greater transparency in price negotiations with concerns with MEAs, development of European collaborations and position statements (EURODIS), and greater use of low cost generics and biosimilars

AB - There are growing concerns among European payers about the rising costs of new medicines especially for cancer and those for orphan diseases, exacerbated by the emotive nature of these disease areas –balanced against continued unmet need▪This is despite the limited health gain of most new medicines coupled with the low cost of goods of most including biological medicines. Alongside this, CEE countries are struggling to fund biological medicines for immunological diseases at Euro 1000 –1500/ patient/ month –although easier with biosimilars ▪This is leading to developments including new models for new medicines incorporating new pricing approaches for orphan diseases, calls for greater transparency in price negotiations with concerns with MEAs, development of European collaborations and position statements (EURODIS), and greater use of low cost generics and biosimilars

KW - pharmaceutical pricing

KW - pharmacoeconomics

KW - health costs

M3 - Other

ER -

Godman B. Access to pharmaceuticals: the EU picture. 2019. AIM event in the European Parliament, Brussels, Belgium.